{{Rsnum
|rsid=2368564
|Gene=REN
|Chromosome=1
|position=204155737
|Orientation=plus
|GMAF=0.3567
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=REN
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 50.4 | 44.2 | 5.3
| HCB | 52.6 | 42.3 | 5.1
| JPT | 69.9 | 23.9 | 6.2
| YRI | 2.7 | 40.1 | 57.1
| ASW | 7.0 | 54.4 | 38.6
| CHB | 52.6 | 42.3 | 5.1
| CHD | 65.1 | 29.4 | 5.5
| GIH | 60.4 | 37.6 | 2.0
| LWK | 10.9 | 37.3 | 51.8
| MEX | 44.8 | 48.3 | 6.9
| MKK | 10.9 | 44.9 | 44.2
| TSI | 51.0 | 41.2 | 7.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2368564
|Name_s=
|Gene_s=
|Feature=
|Evidence=PubMed ID:18794727
|Annotation=The T/T genotype of this SNP was associated with reduced risk of edema resulting from treatment with muraglitazar (BMS-298585) relative to the C/C genotype. The test population consisted of patients with diabetes or hyperlipidemia.
|Drugs=muraglitazar
|Drug Classes=
|Diseases=Diabetes Mellitus; Edema; Hyperlipidemias
|Curation Level=Curated
|PharmGKB Accession ID=PA162361062
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2368564
|overall_frequency_n=53
|overall_frequency_d=128
|overall_frequency=0.414062
|n_genomes=38
|n_genomes_annotated=0
|n_haplomes=50
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}